Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) - a phase 1B/2 trial

Trial Profile

Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) - a phase 1B/2 trial

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary) ; Nivolumab (Primary) ; Calcium; Vitamin D
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Pharmacodynamics
  • Acronyms POPCORN

Most Recent Events

  • 19 Dec 2019 Trial design published in the Trials.
  • 20 Sep 2019 Status changed from not yet recruiting to recruiting.
  • 10 Jul 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top